ebiga-VISION GmbH

𝗲𝗯𝗶𝗴𝗮-𝗩𝗜𝗦𝗜𝗢𝗡 stands for 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲-𝗯𝗮𝘀𝗲𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗴𝗼𝗼𝗱 𝘃𝗶𝘀𝗶𝗼𝗻 𝗮𝘁 𝗮𝗻𝘆 𝗮𝗴𝗲 – a science-driven approach to supporting visual health across all stages of life. Founded in 2010 and based in Greifswald, Germany, the company combines 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 with a clear focus on 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝗾𝘂𝗮𝗹𝗶𝘁𝘆, 𝗮𝗻𝗱 𝘁𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆. 𝗩𝗶𝘀𝗶𝗼𝗻: The potential of targeted micronutrition in eye care remains far from being fully realized. Our aim is to enable eye care professionals and patients to rely on the 𝗽𝗿𝗼𝘃𝗲𝗻 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗼𝗳 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗺𝗶𝗰𝗿𝗼𝗻𝘂𝘁𝗿𝗶𝗲𝗻𝘁 𝘀𝘂𝗽𝗽𝗼𝗿𝘁. This is why 𝘁𝗿𝘂𝘀𝘁 – 𝗯𝘂𝗶𝗹𝘁 𝗼𝗻 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝘂𝗻𝗰𝗼𝗺𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 – is at the heart of everything we do. 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 The efficacy of 𝗩𝗶𝘁𝗿𝗼𝗖𝗮𝗽®𝗡 𝗳𝗼𝗿 𝘃𝗶𝘁𝗿𝗲𝗼𝘂𝘀 𝗳𝗹𝗼𝗮𝘁𝗲𝗿𝘀 has been demonstrated in five clinical studies, including the prospective, double-blind 𝗙𝗹𝗼𝗮𝘁𝗲𝗿 𝗜𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗦𝘁𝘂𝗱𝘆 (𝗙𝗟𝗜𝗘𝗦). Three studies confirm the positive effect of the micronutrient composition in 𝗥𝗲𝘁𝗶𝗖𝗮𝗽®𝗗𝗥 on contrast sensitivity, retinal sensitivity, visual acuity, and retinal thickness in patients with diabetes. Our 𝗺𝗮𝗰𝘂𝗹𝗮𝗿 𝗺𝗶𝗰𝗿𝗼𝗻𝘂𝘁𝗿𝗶𝗲𝗻𝘁𝘀 (such as 𝗠𝗮𝗰𝘂𝗖𝗮𝗽®𝗔𝗠𝗗) are strictly aligned with current guidelines on micronutrient therapy, as established by the 𝗔𝗥𝗘𝗗𝗦/𝗔𝗥𝗘𝗗𝗦2 studies. Our product development also incorporates recent findings from 𝗖𝗥𝗘𝗦𝗧 and 𝗠𝗢𝗦𝗧, highlighting the benefits of 𝗺𝗲𝘀𝗼-𝘇𝗲𝗮𝘅𝗮𝗻𝘁𝗵𝗶𝗻 as the third macular carotenoid. To ensure scientific relevance and innovation, 𝗲𝗯𝗶𝗴𝗮-𝗩𝗜𝗦𝗜𝗢𝗡 maintains active collaboration and exchange with the ophthalmic research and clinical community. We also contribute to knowledge transfer by hosting our own symposia at major international congresses.